Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficilein the piglet model

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Cohen, Ocean R ^a   Steele, Jennifer A ^a   Zhang, Quanshun ^a,b   Schmidt, Diane J ^a   Wang, Yuankai ^a,c   Hamel, Philip E S ^a   Beamer, Gillian ^a   Xu, Bingling ^a   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b Institute for in Vitro Sciences   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TCDA; MONOCLONAL ANTIBODY TCDB; UNCLASSIFIED DRUG; ANTITOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; IMMUNOGLOBULIN G; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TISSUE LEVEL; INFECTION PREVENTION; INTESTINE MUCOSA; MORBIDITY; MORTALITY; NONHUMAN; PIGLET; SYSTEMIC THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; COLON; DISEASE MODEL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMAN; IMMUNOLOGY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PIG;

CLOSTRIDIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COLON; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; HUMANS; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; SWINE;

EID: 84908626313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111075     Document Type: Article

References (17)

1. Sun X, Savidge T, Feng H (2010) The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) 2: 1848-1880.
2. Carter GP, Rood JI, Lyras D (2010) The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut microbes 1: 58-64.
3. McCollum DL, Rodriguez JM (2012) Detection, Treatment, and Prevention of Clostridium difficile Infection. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 10: 581-592.
4. Bakken JS, Polgreen PM, Beekmann S.E., Riedo FX, Streit JA (2013) Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe 24: 20-24.
5. Leav BA, Blair B, Leney M., Knauber M, Reilly C, et al. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28: 965-969.
6. Babcock GJ, Broering TJ, Hernandez H.J., Mandell RB, Donahue K, et al. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74: 6339-6347.
7. Steele J, Mukherjee J, Parry N., Tzipori S (2013) Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis 207: 323-330.
8. Hussack G, Tanha J (2010) Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel) 2: 998-1018.
9. Rath T, Kuo TT, Baker K, Qiao S.W., Kobayashi K., et al. (2013) The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 33 Suppl 1: S9-17.
10. Yoshida M, Kobayashi K, Kuo T.T., Bry L., Glickman JN, et al. (2006) Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest 116: 2142-2151.
11. Lowy I, Molrine DC, Leav B.A., Blair BM, Baxter R, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. The New England journal of medicine 362: 197-205.
12. Taylor CP, Tummala S, Molrine D., Davidson L, Farrell RJ, et al. (2008) Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 26: 3404-3409.
13. Steele J, Feng H, Parry N., Tzipori S (2010) Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis 201: 428-434.
14. Killgore G, Thompson A, Johnson S., Brazier J, Kuijper E, et al. (2008) Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electro-phoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. Journal of Clinical Microbiology 46: 431-437
15. Yang G, Zhou B, Wang J, He X, Sun X, et al. (2008) Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 8: 192.
16. Steele J, Chen K, Sun X., Zhang Y, Wang H, et al. (2012) Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. The Journal of infectious diseases 205: 384-391.
17. Mohawk KL, Melton-Celsa AR, Robinson C.M., O'Brien AD (2010) Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. Vaccine 28: 4777-4785.